Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
NCT00330668
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
114
Enrollment
INDUSTRY
Sponsor class
Stopped
Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day
Conditions
Growth Disorders
Interventions
DRUG:
rh IGF-1 (mecasermin)
Sponsor
Ipsen